Multi-Attribute Methods (MAM) leverage high-resolution Mass Spectrometry (LC-MS) to replace legacy profile-based assays by simultaneously identifying, quantifying, and monitoring multiple Critical Quality Attributes (CQAs)—such as glycosylation and deamidation—in a single run.
Biosimilar Characterization places a higher analytical burden on biopharmaceutical developers because proving totality of evidence requires rigorous comparative testing of primary sequences, higher-order structures, and Post-Translational Modifications (PTMs) against innovator reference products.
Real-Time Process Monitoring using non-destructive Raman Spectroscopy shifts quality testing out of offline laboratories and directly onto the manufacturing floor, enabling tight process feedback loops required for Continuous Processing.
Automation and Robotic Sample Handling eliminate human error in sample preparation, substantially accelerating assay throughput while delivering the robust, high-volume datasets necessary to drive Quality by Design (QbD) initiatives.
Laboratory Information Management Systems (LIMS) provide the foundational digital infrastructure needed to manage complex high-throughput data volumes, ensure regulatory data integrity, and support seamless equipment software integration.
1. Analytical Technologies
1.1. The highly complex nature of biopharmaceuticals places a significant burden on analytical methods and data to support discovery, development, regulatory approval, manufacture, and release. In addition to primary and secondary amino acid sequences and structure, posttranslational modifications — glycosylation, phosphorylation, deamidation, and so on — must all be closely monitored. Product-related impurities, host cell proteins, process impurities, and contaminating species must also be tested and identified. Raw materials must be properly identified; water and air quality must be maintained to rigorous standards; and cleanrooms and surfaces must be monitored for contamination. The stability of intermediate products during processing must be validated, as must the stability of the final product in both its drug substance and drug product forms.
1.2. The analytical burden is greater for biosimilars, where rigorous characterization is required to demonstrate that the product is essentially the same as the innovator reference product.
1.3. Many recent advances in analytical methodology in the bioprocessing space are related to the reduction of human error via sample collection and handling in order to increase speed and improve quality. Systems are becoming increasingly automated, and robotic handling systems are now in widespread use. Vendors continue to introduce new products at a dizzying pace. These advances also allow a vastly increased number of analyses to be performed, increasing the quality of data and empowering QbD initiatives. Companies such as Tecan are focused on improving workflows and rapid data delivery.
1.4. A number of well-recognized analytical methods, such as enzyme-linked immunosorbent assays (ELISA), liquid chromatographic methods, capillary isoelectric focusing (CIEF), and capillary gel electrophoresis (CGE), remain the workhorses for release and stability testing of biopharmaceuticals based on their robustness and relative simplicity.
1.5. More detailed characterization requires additional methods. Mass spectrometry for peptide mapping and the use of various liquid chromatographic methodologies, such as high-performance liquid chromatography (HPLC) and ultra-high-performance liquid chromatography (UHPLC), are prominent. Of note is the emergence of multi-attribute methods (MAMs). This approach essentially combines liquid chromatography and mass spectrometry for peptide mapping that can confirm amino acid sequences and also examine site-specific modifications to identify variation in glycosylation pattern, change profile, and other attributes. The potential exists for MAM to replace profile-based techniques and to eliminate the need for multiple, widely used existing chromatographic and electrophoresis techniques.
1.6. Mass spectrometry–based identity methods are increasingly being employed for release testing in the quality setting, and this approach is likely to gain more widespread acceptance as regulatory authorities become comfortable and demand additional data.
1.7. The need for rapid analysis and feedback during bioprocessing is being accentuated by the move toward continuous processing. Taking samples “offline” and waiting for results to be delivered from traditional laboratory-based methods typically cannot provide representative data quickly enough to support intimate process control. Significant development is ongoing in support of real-time process monitoring of cell growth, chromatography feeds, and chromatography eluents. The goal of such efforts is to move quality out of the lab and onto the manufacturing floor. Various spectroscopy and biosensor technologies have the potential to provide rapid feedback. In particular, Raman spectroscopy is now being adopted in the manufacture of small molecule APIs and has significant potential to support real-time monitoring of biopharmaceutical processes.
1.8. These advances — together with dramatic increases in the volume and variety of data collected and the speed at which it must be processed — require parallel digital innovations to support data collection, storage and retrieval, analysis, and presentation, in ways acceptable to both scientists and regulators. Laboratory information management systems (LIMS) are now widely employed to manage data and ensure data integrity, but beyond this, sophisticated software tools that can be integrated with processing equipment are required.
FAQs
What is the Multi-Attribute Method (MAM) in biopharmaceutical testing?
The Multi-Attribute Method (MAM) is an advanced mass spectrometry (LC-MS) workflow that simultaneously identifies, quantifies, and monitors multiple Critical Quality Attributes (CQAs) of biopharmaceuticals in a single assay. MAM replaces legacy electrophoretic and chromatographic assays by directly tracking post-translational modifications (PTMs), sequence variations, and product impurities during batch release.
Why is detailed characterization more critical for biosimilar approval?
Detailed characterization is required for biosimilars to establish total analytical comparability with the innovator reference product. Regulators mandate extensive testing of primary sequences, higher-order structures, and post-translational modifications like glycosylation to confirm that minor structural differences do not alter safety, purity, or clinical efficacy profiles.
How does real-time process monitoring support continuous bioprocessing?
Real-time process monitoring utilizes in-line spectroscopy tools like Raman spectroscopy to deliver instant analytical feedback directly from the manufacturing floor. By replacing offline laboratory testing, real-time feedback enables immediate process control, stabilizes culture conditions, maintains Critical Quality Attributes (CQAs), and aligns with Process Analytical Technology (PAT) frameworks.
What traditional analytical methods remain the workhorses for biopharma release testing?
Traditional workhorses like ELISA, high-performance liquid chromatography (HPLC), capillary isoelectric focusing (CIEF), and capillary gel electrophoresis (CGE) remain standard for release and stability testing. They are widely utilized across quality control environments due to their proven robustness, regulatory acceptance, low complexity, and high reproducibility.
What role do Laboratory Information Management Systems (LIMS) play in bioprocess data integrity?
Laboratory Information Management Systems (LIMS) automate data collection, storage, and retrieval across automated analytical workflows to maintain strict regulatory data integrity. LIMS prevents human transcription error, enforces Quality by Design (QbD) standards, and integrates high-throughput instrument data from robotic sample handling systems into compliant audit trails.
How does automated sample handling improve Quality by Design (QbD) initiatives?
Automated sample handling reduces human error and accelerates processing speed during biopharmaceutical characterization. By integrating robotic sample preparation with high-throughput testing systems, biopharma laboratories collect larger volumes of high-quality analytical data, which strengthens statistical process modeling and directly empowers Quality by Design (QbD) optimization.
